Innovent Biologics Company Top Insiders

IVBXF Stock  USD 4.85  0.24  4.72%   
Innovent Biologics employs about 5.5 K people. The company is managed by 10 executives with a total tenure of roughly 12922 years, averaging almost 1292.0 years of service per executive, having 553.8 employees per reported executive. Examination of Innovent Biologics' management performance can provide insight into the company performance.
Min Liu  Insider
Chief Officer
Blake Salisbury  Insider
Sr Devel
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innovent Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Innovent Biologics Management Team Effectiveness

The company has return on total asset (ROA) of (0.1372) % which means that it has lost $0.1372 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.287) %, meaning that it generated substantial loss on money invested by shareholders. Innovent Biologics' management efficiency ratios could be used to measure how well Innovent Biologics manages its routine affairs as well as how well it operates its assets and liabilities.

Innovent Biologics Workforce Comparison

Innovent Biologics is currently regarded as number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 5,555. Innovent Biologics totals roughly 5,538 in number of employees claiming about 100% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of (0.68) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.78) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.78.

Innovent Biologics Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Innovent Biologics Price Series Summation is a cross summation of Innovent Biologics price series and its benchmark/peer.

Innovent Biologics Notable Stakeholders

An Innovent Biologics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Innovent Biologics often face trade-offs trying to please all of them. Innovent Biologics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Innovent Biologics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.

About Innovent Biologics Management Performance

The success or failure of an entity such as Innovent Biologics often depends on how effective the management is. Innovent Biologics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Innovent management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Innovent management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the Peoples Republic of China. Innovent Biologics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5538 people.

Innovent Biologics Workforce Analysis

Traditionally, organizations such as Innovent Biologics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Innovent Biologics within its industry.

Innovent Biologics Manpower Efficiency

Return on Innovent Biologics Manpower

Revenue Per Employee771K
Revenue Per Executive427M
Net Loss Per Employee566.6K
Net Loss Per Executive313.8M

Complementary Tools for Innovent Pink Sheet analysis

When running Innovent Biologics' price analysis, check to measure Innovent Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovent Biologics is operating at the current time. Most of Innovent Biologics' value examination focuses on studying past and present price action to predict the probability of Innovent Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovent Biologics' price. Additionally, you may evaluate how the addition of Innovent Biologics to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Transaction History
View history of all your transactions and understand their impact on performance
Equity Valuation
Check real value of public entities based on technical and fundamental data